IR情報

2022/05/20~2022/10/13

IR情報&株価推移

日付始値高値安値終値前日比出来高時価総額25日乖離
2022
10/134,5964,6374,5694,593-0.07%765,2002兆5621億+0.5%
10/124,6004,6314,5844,596-0.02%872,5002兆5638億+0.68%
10/114,6144,6344,5614,597-1.27%1,137,1002兆5643億+0.75%
10/074,6464,6824,6264,656-0.43%925,8002兆5972億+2.11%
10/064,7024,7244,6584,676-0.26%838,7002兆6084億+2.63%
10/054,7004,7274,6644,688-0.02%974,3002兆6151億+3.03%
10/044,6214,6974,6134,689+2.25%1,069,3002兆6156億+3.17%
10/034,5744,5864,5214,586+0.04%1,026,5002兆5582億+0.99%
09/304,6124,6404,5574,584-0.07%1,759,1002兆5571億+0.92%
09/294,5164,6024,5024,587+3.17%1,244,7002兆5587億+0.99%
09/284,4284,4554,3984,446-0.49%1,536,5002兆4801億-2.16%
09/274,4354,4964,4344,468+0.9%856,6002兆4924億-1.93%
09/264,4214,4564,4004,428-0.94%1,301,9002兆4700億-2.98%
09/224,4574,4754,4104,470-0.49%1,146,3002兆4935億-2.32%
09/214,5084,5244,4744,492-1.19%773,2002兆5057億-2.03%
09/204,5324,5594,5264,546+0.35%887,5002兆5359億-1.04%
09/208:30 Paradise超音波腎デナベーションシステムTCT年次総会でRADIANCE-II米国ピボタル試験データを発表
09/164,5004,5464,4924,530-0.04%1,210,8002兆5269億-1.54%
09/154,5344,5414,4994,532-0.15%621,3002兆5281億-1.63%
09/144,5344,5544,5114,539-2.01%836,5002兆5320億-1.56%
09/1315:15 アリピプラゾール2カ月持続性注射剤統合失調症と双極I型障害の適応で米国FDAが申請受理
09/134,6584,6694,6284,632-0.24%555,5002兆5838億+0.37%
09/1215:00 抗精神病薬「ブレクスピプラゾール」大うつ病を対象とした国内フェーズ3試験で主要評価項目を達成
09/124,6614,6654,6154,643-0.24%566,0002兆5900億+0.56%
09/094,6024,6794,5994,654+1.2%1,347,9002兆5961億+0.8%
09/084,5674,6044,5594,599+2.38%1,002,0002兆5654億-0.35%
09/074,5474,5604,4534,492-0.77%1,008,7002兆5057億-2.64%
09/064,5134,5524,5064,527+1.18%754,1002兆5253億-1.93%
09/054,4664,4974,4404,474-1.37%840,3002兆4957億-3.26%
09/024,5514,5594,5024,536+0.22%873,3002兆5303億-2.16%
09/014,5304,5524,5204,526-0.77%660,4002兆5247億-2.69%
08/314,5094,5704,5094,561+0.62%1,282,9002兆5442億-2.25%
08/304,5554,5864,5284,533-0.37%677,3002兆5286億-3.12%
08/294,5314,5614,5094,550-1.11%781,0002兆5381億-3.11%
08/264,5974,6334,5884,601+0.17%463,7002兆5666億-2.36%
08/254,6054,6194,5674,593+0.17%621,6002兆5621億-2.83%
08/244,6044,6144,5574,585-1.46%730,6002兆5576億-3.29%
08/234,7244,7284,6334,653-1.84%906,4002兆5956億-2.08%
08/224,7094,7534,6544,740+1.56%861,1002兆6441億-0.46%
08/194,7054,7154,6624,667-0.98%730,1002兆6034億-2.16%
08/184,7134,7224,6644,713-0.13%1,138,3002兆6290億-1.42%
08/174,6684,7324,6504,719+0.53%1,018,6002兆6324億-1.48%
08/164,7134,7224,6624,694-0.68%656,2002兆6184億-2.21%
08/154,6854,7404,6824,726+0.81%563,9002兆6363億-1.71%
08/124,6894,7164,6654,688+1.49%1,293,7002兆6151億-2.72%
08/104,6554,6704,5824,619-0.54%1,019,0002兆5766億-4.35%
08/094,6774,7084,6284,644-0.77%841,0002兆5905億-4.05%
08/084,6354,6934,6224,680+0.45%744,8002兆6106億-3.49%
08/054,6114,6644,6004,659+1.53%1,188,8002兆5989億-4%
08/044,7194,7194,5544,589+0.22%1,239,4002兆5599億-5.56%
08/034,6484,6484,5624,579+0.53%1,265,2002兆5543億-5.94%
08/024,6704,6814,5504,555-3.86%1,045,8002兆5409億-6.7%
08/014,7224,7704,7114,738-0.34%1,013,3002兆6430億-3.15%
07/2913:30 2022年12月期第2四半期決算短信〔IFRS〕(連結)
07/294,9444,9484,6914,754-3.04%1,710,2002兆6519億-2.66%
07/284,8994,9204,8264,903+0.14%1,241,9002兆7350億+0.57%
07/274,8664,9134,7864,896+0.18%1,530,8002兆7311億+0.76%
07/2616:00 Paradise超音波腎デナベーションシステム高血圧患者対象のRADIANCE-II米国ピボタル試験にて主要評価項目を達成
07/2616:00 業績予想の修正に関するお知らせ
07/264,9424,9584,8764,887-1.39%792,9002兆7261億+0.97%
07/254,9554,9904,9234,956+0.08%665,1002兆7646億+2.8%
07/224,9764,9834,9004,952-0.52%797,3002兆7624億+3.23%
07/214,9024,9874,8994,978+0.79%840,9002兆7769億+4.27%
07/204,9064,9494,8794,939+1.56%955,3002兆7551億+4.04%
07/194,9024,9144,8384,863-1.1%645,5002兆7127億+2.92%
07/154,9414,9664,8984,917-0.43%866,0002兆7428億+4.42%
07/144,9104,9604,8754,938+0.2%915,3002兆7545億+5.31%
07/134,9374,9764,9154,928-0.36%809,4002兆7490億+5.52%
07/124,9544,9854,9244,946-0.76%1,058,4002兆7590億+6.37%
07/114,9495,0004,9204,984+2.15%1,163,9002兆7802億+7.72%
07/084,9504,9624,8324,879-2.42%1,593,5002兆7216億+6.02%
07/074,9725,0004,9235,000+1.32%1,391,0002兆7891億+9.15%
07/064,8674,9644,8604,935+0.8%1,508,2002兆7529億+8.39%
07/054,8814,8964,8304,896+0.29%1,055,0002兆7311億+8.06%
07/044,9004,9294,8404,882+2.37%1,104,4002兆7233億+8.32%
07/014,8584,9044,7534,769-1.02%1,080,5002兆6603億+6.28%
06/304,8154,8614,8114,818+0.27%1,439,5002兆6876億+7.81%
06/294,8504,8784,7934,805-2.63%1,703,8002兆6804億+7.95%
06/284,8094,9504,7974,935+2.88%1,611,7002兆7529億+11.27%
06/274,5674,8054,5184,797+5.38%2,104,9002兆6759億+8.6%
06/279:00 抗精神病薬「ブレクスピプラゾール」アルツハイマー型認知症に伴う行動障害を対象としたグローバルフェーズ3試験で主要評価項目を達成し有効性を確認
06/244,5604,5654,4994,552+0.6%702,6002兆5392億+3.34%
06/234,4904,5544,4904,525+0.67%754,3002兆5242億+2.82%
06/224,4654,5174,4534,495+1.33%735,1002兆5074億+2.18%
06/214,4304,4624,3794,436+0.66%904,2002兆4745億+0.8%
06/204,4134,4474,3804,407+1.08%552,2002兆4583億+0.11%
06/1717:30 アリピプラゾール2ヵ月持続性注射剤統合失調症の適応で欧州医薬品庁が申請受理
06/174,3224,3884,3074,3600%1,339,7002兆4321億-0.95%
06/164,3784,4154,3584,360+1.14%704,0002兆4321億-0.91%
06/154,3944,3954,3064,311-1.64%764,4002兆4048億-2.07%
06/144,4064,4264,3664,383-1.66%862,5002兆4449億-0.52%
06/134,3814,4644,3814,457+0.47%835,8002兆4862億+1.09%
06/104,4744,4744,4244,436-0.65%1,085,1002兆4745億+0.64%
06/094,4504,4924,4314,465+0.81%865,8002兆4907億+1.22%
06/084,3964,4334,3654,429+1.72%796,6002兆4706億+0.43%
06/074,3304,3794,3204,354-0.25%801,4002兆4288億-1.2%
06/064,3204,3764,3164,365+0.55%732,6002兆4349億-0.82%
06/034,3424,3684,3214,341+0.56%771,0002兆4215億-1.27%
06/024,3754,3834,3044,317-1.48%954,3002兆4081億-1.73%
06/014,3404,4324,3244,382+2.17%1,198,6002兆4444億-0.18%
05/314,3914,4224,2894,289-2.01%5,562,7002兆3925億-2.19%
05/304,3494,4104,3304,377+1.06%1,250,0002兆4416億-0.07%
05/274,4004,4094,3134,331-0.57%889,4002兆4159億-0.89%
05/264,4094,4414,3544,356-1.6%1,167,2002兆4299億-0.14%
05/254,4754,4824,4264,427-0.9%978,0002兆4695億+1.63%
05/244,4984,5094,4624,467-0.8%819,3002兆4918億+2.71%
05/234,4904,5224,4534,503+1.4%1,019,7002兆5119億+3.8%
05/204,4744,4944,4354,441-0.98%1,392,1002兆4773億+2.68%
05/1313:30 大塚製薬とアケビア社の腎性貧血治療薬におけるグローバルライセンス契約の終了について
05/1313:30 2022年12月期第1四半期決算短信〔IFRS〕(連結)